[Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine. Sixty five percent of patients had objective response with 25% complete response rate. Tolerance of treatment was satisfactory. Only in 1 patients side effects were the reason of treatment interruption. Amifostine markedly decreases chemotherapy toxicity, mainly hematological and does not seem to influence the efficacy of chemotherapy.
Pawlicki
M
M
Kliniki Chemioterapii Centrum Onkologii, Oddział w Krakowie.
Rolski
J
J
Wiczyńska
B
B
Rychlik
U
U
D000328:Adult; D000368:Aged; D004999:Amifostine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D016896:Treatment Outcome
D011837:Radiation-Protective Agents; D003520:Cyclophosphamide; D004999:Amifostine; D002945:Cisplatin